Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | CASR | P41180 | 2/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43735 | 1.00 | AOC3 (0.57) | AOC3L3MBTL1CASRCHRM2CHRM1 | |
| SCHEMBL43520 | 1.00 | AOC3 (0.57) | AOC3L3MBTL1CASRCHRM2CHRM1 | |
| SCHEMBL2608969 | 0.86 | AOC3 (0.58) | AOC3L3MBTL1CASRCHRM2CHRM1 | |
| SCHEMBL6912472 | 0.85 | PTGS1 (0.58) | AOC3L3MBTL1UGT2B7ACHE | |
| SCHEMBL6912468 | 0.85 | PTGS1 (0.58) | AOC3L3MBTL1UGT2B7ACHE | |
| SCHEMBL2093768 | 0.85 | AOC3 (0.59) | AOC3L3MBTL1CASRCHRM2CHRM1 | |
| SCHEMBL2087869 | 0.85 | AOC3 (0.59) | AOC3L3MBTL1CASRCHRM2CHRM1 | |
| SCHEMBL11604883 | 0.85 | AOC3 (0.62) | AOC3L3MBTL1CASRCHRM2CHRM1 | |
| SCHEMBL24925808 | 0.84 | AOC3 (0.54) | AOC3L3MBTL1CASRCHRM2CHRM1 | |
| SCHEMBL18793772 | 0.84 | AOC3 (0.54) | AOC3L3MBTL1CASRCHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10882819-B2 | Synthesis of novel intermediate(s) for preparing rivastigmine | Cadila Corporate Campus (IN) | 2021-01-05 | — | — | US | disclosed |
| US-10882819-B2 | Synthesis of novel intermediate(s) for preparing rivastigmine | Cadila Corporate Campus (IN) | 2021-01-05 | — | — | US | disclosed |
| US-20200095195-A1 | SYNTHESIS OF NOVEL INTERMEDIATE(S) FOR PREPARING RIVASTIGMINE | CADILA PHARMACEUTICALS, LTD. (IN) | 2020-03-26 | — | — | US | disclosed |
| US-20200095195-A1 | SYNTHESIS OF NOVEL INTERMEDIATE(S) FOR PREPARING RIVASTIGMINE | CADILA PHARMACEUTICALS, LTD. (IN) | 2020-03-26 | — | — | US | disclosed |
| US-9321045-B2 | Catalyst and process for synthesising the same | THE UNIVERSITY OF WARWICK (GB) | 2016-04-26 | — | — | US | disclosed |
| US-9321045-B2 | Catalyst and process for synthesising the same | THE UNIVERSITY OF WARWICK (GB) | 2016-04-26 | — | — | US | disclosed |
| US-20150290634-A1 | Catalyst and Process for Synthesising the Same | THE UNIVERSITY OF WARWICK (GB) | 2015-10-15 | — | — | US | disclosed |
| US-20150290634-A1 | Catalyst and Process for Synthesising the Same | THE UNIVERSITY OF WARWICK (GB) | 2015-10-15 | — | — | US | disclosed |
| EP-2914609-A1 | CATALYST AND PROCESS FOR SYNTHESISING THE SAME | THE UNIVERSITY OF WARWICK (GB) | 2015-09-09 | — | — | EP | disclosed |
| CN-104837854-A | Catalyst and process for synthesising the same | UNIV WARWICK | 2015-08-12 | — | — | CN | disclosed |
| US-20120015991-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-8058300-B2 | Polycyclic antagonists of lysophosphatidic acid receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| WO-2010141768-A2 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010141768-A2 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010141761-A2 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| US-20100311799-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-7108896-B2 | Method of increasing helical twisting power, optically active compound, liquid crystal compostion containing the same, and liquid crystal display device | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2006-09-19 | — | — | US | disclosed |
| US-20040021128-A1 | Method of increasing helical twisting power, optically active compound, liquid crystal composition containing the same, and liquid crystal display device | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2004-02-05 | — | — | US | disclosed |
| US-20030171544-A1 | Alcohol dehydrogenase and use thereof | DEGUSSA AG (DE) | 2003-09-11 | — | — | US | disclosed |
| EP-1241263-A1 | Alcohol dehydrogenase and uses therefor | Degussa AG (DE) | 2002-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882819-B2 | Synthesis of novel intermediate(s) for preparing rivastigmine | ACHE, SQLE, BCHE | AOC3 1315/4885L3MBTL1 4629/4885CASR 4773/4885 |
| US-20200095195-A1 | SYNTHESIS OF NOVEL INTERMEDIATE(S) FOR PREPARING RIVASTIGMINE | ACHE, SQLE, BCHE | AOC3 1315/4885L3MBTL1 4629/4885CASR 4773/4885 |
| US-20150290634-A1 | Catalyst and Process for Synthesising the Same | CBR3, SPR, RNF5 | AOC3 207/4885L3MBTL1 3121/4885CASR 4733/4885 |
| US-20030171544-A1 | Alcohol dehydrogenase and use thereof | ADH5, ADH1A, ADH1C | AOC3 801/4885L3MBTL1 2989/4885CASR 4711/4885 |
| US-20100311799-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | AOC3 2482/4885L3MBTL1 2613/4885CASR 203/4885 |
| US-20120015991-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | AOC3 2482/4885L3MBTL1 2613/4885CASR 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.